India Molecular Diagnostics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

India's molecular diagnostics market represents a rapidly expanding segment of the country's overall diagnostic laboratories industry, which was valued at approximately $18.55 billion in 2025. The molecular diagnostics segment itself, covering technologies such as PCR, NGS, FISH, and in-situ hybridization, has become a critical tool for infectious disease detection, oncology screening, prenatal testing, and personalized medicine. Government agencies including the Ministry of Health and Family Welfare have expanded laboratory infrastructure networks, particularly for tuberculosis control programs utilizing molecular testing platforms.

• •Market valued at approximately $1.23 billion in 2025, with broader India diagnostic labs market at $18.55 billion
• •Molecular diagnostics heavily drives growth within the pathology sector, outpacing conventional diagnostic segments
• •Government infrastructure updates tracked through health ministry programs, particularly TB laboratory networks

The market's expansion is anchored by India's rising burden of chronic and infectious diseases, an aging population, and increasing demand for early and accurate disease detection. Government initiatives such as the National TB Elimination Programme have institutionalized molecular testing at scale through widespread deployment of CBNAAT machines. Additionally, growing health insurance penetration, medical tourism, and the proliferation of private diagnostic chains in tier-2 and tier-3 cities are expanding access to advanced molecular testing.

• •Government TB elimination program relies extensively on molecular diagnostics (CBNAAT), driving institutional demand
• •Medical tourism and rising middle-class healthcare spending fuel demand for advanced testing
• •Diagnostic laboratories market overall projected at 10.42-11.70% CAGR through 2030, with molecular segment leading growth

By technology, PCR-based tests dominate the market, holding approximately 43.44% share globally in the Asia-Pacific molecular diagnostics space as of 2025. The market is segmented by application into infectious diseases (particularly TB, HIV, hepatitis), oncology, genetic disorders, and prenatal testing, with infectious disease testing representing the largest application segment. Geographically, urban centers and metro cities concentrate high-end molecular testing, while tier-2 and tier-3 cities are emerging as key growth frontiers as private lab networks expand.

• •PCR technology holds dominant market share (~43.44% in 2025 in Asia-Pacific region)
• •Infectious disease testing, especially TB, is the largest application segment
• •Tier-2 and tier-3 cities represent emerging growth markets as private diagnostic chains expand reach

What are the recent trends and outlook?

Looking forward, the market is expected to continue its upward trajectory through 2030-2034, with conservative projections placing it between $1.41 billion and $1.70 billion by 2030, and more aggressive forecasts suggesting growth toward $2.8 billion by 2034. Key trends include the integration of automation and AI-powered diagnostics, increasing adoption of point-of-care molecular testing, and growing emphasis on personalized medicine and companion diagnostics. The Asia-Pacific region overall is forecast to achieve the highest global CAGR in molecular diagnostics, positioning India as a key growth engine within the regional market.

• •Market projected to reach $1.41-$1.71 billion by 2030, with some forecasts extending to $2.8 billion by 2034
• •Automation, AI-powered diagnostics, and point-of-care molecular testing are emerging as dominant trends
• •Asia-Pacific region leads global molecular diagnostics CAGR growth (~11.35% from 2026-2031), with India as a primary contributor